No two strokes are alike - the damage from each stroke leaves its own unique signature on a person's brain and behaviour. The current project will investigate how different types of stroke affect a person's long term recovery or deterioration
The European Stroke Organisation Conference (ESOC) 2018 is currently on from 16-18 May in Gothenburg, Sweden. The first day of ESOC included some truly inspiring scientific sessions, including the WAKE-UP trial, RIGHT-2 trial and CROMIS-2 trials.
Postgraduate fellowship: What is the impact of damaged thinking ability caused by a spontaneous bleed in the brain?
Published in the journal Age and Ageing, a new systematic review of the current research suggests that anticoagulant drugs may have cognitive benefit for those with AF (atrial fibrillation).
The National Institute of Clinical Excellence (NICE) are currently welcoming applications from people who would like to join the groups that develop Quality Standards.
The aim of this programme is to develop and test a new care pathway for paramedics to recognise the patients who are likely to have a large artery blockage, so that this group can be taken directly to the thrombectomy hospital.
Currently, a drug called alteplase is used in thrombolysis, but the researchers think that another drug, called tenecteplase, may be more effective than alteplase.
A panel of independent experts has decided that alteplase, a clot-busting drug often used to treat strokes is safe and effective under current guidelines.
This study will test arm training to encourage a functionally useful contribution to recovery from the side of the brain unaffected by stroke (the 'non-stroke hemisphere'), and whether this is only possible early after stroke.